Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Taysha Gene Therapies (TSHA) Assets Average (2022 - 2025)

Historic Assets Average for Taysha Gene Therapies (TSHA) over the last 4 years, with Q3 2025 value amounting to $324.9 million.

  • Taysha Gene Therapies' Assets Average rose 7074.83% to $324.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $324.9 million, marking a year-over-year increase of 7074.83%. This contributed to the annual value of $166.5 million for FY2024, which is 1140.04% up from last year.
  • As of Q3 2025, Taysha Gene Therapies' Assets Average stood at $324.9 million, which was up 7074.83% from $235.8 million recorded in Q2 2025.
  • Over the past 5 years, Taysha Gene Therapies' Assets Average peaked at $324.9 million during Q3 2025, and registered a low of $91.6 million during Q2 2023.
  • Its 4-year average for Assets Average is $167.0 million, with a median of $158.5 million in 2022.
  • In the last 5 years, Taysha Gene Therapies' Assets Average tumbled by 4059.74% in 2023 and then skyrocketed by 9295.96% in 2024.
  • Over the past 4 years, Taysha Gene Therapies' Assets Average (Quarter) stood at $118.9 million in 2022, then skyrocketed by 55.0% to $184.2 million in 2023, then fell by 7.58% to $170.3 million in 2024, then surged by 90.82% to $324.9 million in 2025.
  • Its Assets Average was $324.9 million in Q3 2025, compared to $235.8 million in Q2 2025 and $149.4 million in Q1 2025.